Cardiovascular Complications
Some problems of the heart may also affect the liver and vice versa. Mild changes in liver function in heart failure, shock liver, congestive liver fibrosis, and congestive hepatopathy are all heart illnesses that impact the liver. On the other hand, complications of cirrhosis, such as hepatopulmonary syndrome, noncirrhotic cardiac disorders, pulmonary arterial hypertension, and cardiac tamponade, are among the liver diseases associated with NAFLD affect the heart.
In addition, restricted expandability, insulin resistance, and dysfunctionality of body fat play considerably larger roles in the clinical development of NAFLD. As a hepatic manifestation of the metabolic syndrome, NAFLD is often accompanied by other metabolic comorbidities, including type 2 diabetes, obesity, or hyperlipidemia. NAFLD is linked to both preclinical and clinical stages of cardiovascular disease, and it may also create complications inside the liver itself.
There is mounting evidence that people with NAFLD have an elevated risk of developing cardiovascular complications such as high blood pressure, ischemic cardiomyopathy, coronary heart disease, and cardiac dysrhythmia.
Patients with alcoholic steatohepatitis, severe liver fibrosis, and NAFLD patients with associated type 2 diabetes mellitus have the highest risk for cardiovascular diseases. In fact, 20 to 55 percent of NAFLD patients have cardiovascular complications.
